ASCRS 2023: Cenegermin 0.002%: Effective for corneal nerve regeneration in neurotrophic keratitis

Article

In a presentation at the American Society for Cataract and Refractive Surgery annual meeting in San Diego, Ana Balbuena-Pareja, MSc, explained how cenegermin-bkbj ophthalmic solution 0.002% (Oxervate, Dompé) had a positive effect on corneal nerve regeneration and sensation in patients with neurotrophic keratitis.

Image Credit: © WavebreakmediaMicro - stock.adobe.come

The authors concluded that the patients with neurotrophic keratitis who were treated for at least 4 weeks with cenegermin 0.002% had an overall increase in the total, main, and branch nerve densities. These results also demonstrated a significant increase in corneal sensation after cenegermin treatment. (Adobe Stock/WavebreakmediaMicro)

Ana Balbuena-Pareja, MSc, and colleagues from Tufts Medical Center, Boston, reported that cenegermin-bkbj ophthalmic solution 0.002% (Oxervate, Dompé) had a positive effect on corneal nerve regeneration and sensation in patients with neurotrophic keratitis. The investigators reported their findings at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in San Diego.

The authors carried out a retrospective study of patients seen at the New England Eye Center for neurotrophic keratitis from January 1, 2015, to March 31, 2022.All eligible patients completed a minimum of 4 weeks of treatment with cenegermin 0.002% and had in vivo confocal microscopy images from before and after treatment available.

For each evaluation, 3 representative in vivo confocal microscopy images were selected and graded in a masked fashion for total, main, and branch nerve density.

The group comprised of 25 patients with neurotrophic keratitis (mean age, 64.2; 28.0% male) and the control group that included 20 patients (mean age, 58.4; 40%male) were similar in age and sex.

The results showed that the median total, main, and branch nerve densities were lower in the neurotrophic keratitis group before treatment, respectively, 2,301.0, 1,653.5, and 547.9 µm/mm² compared with the respective controls values, 22,253.7, 10,130.95, and 12,080.9 (p<0.001 for all comparisons).

Following treatment with cenegermin, the densities increased to 5,306.7 for total (p=0.004), main 3,452.0 (p=0.005), and branch 1,987.9 (p=0.019) nerve densities. Corneal sensation also increased after treatment from 2.3 cm to 4.1 cm (p=0.001).

The authors concluded that the patients with neurotrophic keratitis who were treated for at least 4 weeks with cenegermin 0.002% had an overall increase in the total, main, and branch nerve densities. These results also demonstrated a significant increase in corneal sensation after cenegermin treatment.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Karl Stonecipher ASCRS 2025
AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO; provided their insights during CIME 2025 on May 4.
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
© 2025 MJH Life Sciences

All rights reserved.